Old Web
English
Sign In
Acemap
>
authorDetail
>
Jie Li
Jie Li
Center for Drug Evaluation and Research
Medicine
Obstetrics
Omalizumab
Cancer
Proportional hazards model
5
Papers
19
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Phosphodiesterase type 5 inhibitor use among pregnant and reproductive-age women in the United States.
2020
Pharmacoepidemiology and Drug Safety
Wei Liu
Talia J. Menzin
Corinne Woods
Nicole R. Haug
Jie Li
Justin Mathew
Christine P. Nguyen
Grace Chai
David Moeny
Mayura Shinde
Show All
Source
Cite
Save
Citations (2)
Association of Risk for Venous Thromboembolism With Use of Low-Dose Extended- and Continuous-Cycle Combined Oral Contraceptives: A Safety Study Using the Sentinel Distributed Database
2018
JAMA Internal Medicine
Jie Li
Genna Panucci
David Moeny
Wei Liu
Judith C. Maro
Sengwee Toh
Ting‐Ying Huang
Show All
Source
Cite
Save
Citations (4)
The Effect of FDA Drug Safety Communications on Patterns of Tiotropium Dispensing: A U.S. Health Plan Claims Database Study.
2018
Journal of Managed Care Pharmacy
Jacqueline M. Major
Esther H. Zhou
Yulan Ding
Thomas Ly
Jie Li
Simone P. Pinheiro
Sally Seymour
Show All
Source
Cite
Save
Citations (0)
EXCELS study results do not rule out potential cancer risk with omalizumab
2015
The Journal of Allergy and Clinical Immunology
Jie Li
Margie R. Goulding
Sally Seymour
Peter R. Starke
Show All
Source
Cite
Save
Citations (13)
EXCELS study results do not rule out potential cancer risk with omalizumab
2014
The Journal of Allergy and Clinical Immunology
Jie Li
Margie R. Goulding
Sally Seymour
Peter R. Starke
Show All
Source
Cite
Save
Citations (0)
1